CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL

December 11-14, 2021; Atlanta, Georgia
Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 2-year DFS rate of 95.3% in patients with undetectable MRD who were subsequently randomized to placebo and 100% in those subsequently randomized to ibrutinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 206 KB
Released: December 21, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slides on hypersensitivity reactions associated with asparaginase-based regimens in the treatment of ALL, from Clinical Care Options (CCO)

Kjeld Schmiegelow, MD, DMSci Released: December 9, 2022

Downloadable slideset on management strategies for patients with lower or intermediate-risk MDS from Clinical Care Options (CCO)

María Díez Campelo, MD, PhD
Program Director
Released: December 9, 2022

Downloadable slideset by Amer M. Zeidan, MBBS, on current and evolving treatment of higher risk MDS, from Clinical Care Options (CCO)

Amer Zeidan, MBBS, MPH
Program Director
Released: December 9, 2022

Downloadable slideset on BTK inhibitors for the frontline treatment of CLL/SLL from Clinical Care Options (CCO).

Susan M. O'Brien, MD Released: December 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings